文献速递神经肿瘤

多形性胶质母细胞瘤中NETosis相关生物标志物的评估:PAD4作为强效诊断预测因子

Evaluation of NETosis-related biomarkers in glioblastoma multiforme: PAD4 as a potent diagnostic predictor.
PubMed 文献 · J Neurooncol · 2026-02-17

这项前瞻性观察研究纳入42例经组织病理学确诊的GBM手术患者和38例颅内脑膜瘤(WHO I–III级)对照,采用ELISA检测术中肿瘤组织及配对术前血清中PAD4、MPO、NE和citH3水平。结果显示GBM组肿瘤组织中NE、PAD4、MPO和citH3均显著高于对照组(均p<0.0001),血清中仅NE显著升高(p<0.05);组织PAD4的ROC曲线下面积达0.9568,判别效能最高,logistic回归中PAD4是最强的GBM预测因子。

要点

  • GBM肿瘤组织中NETosis相关标志物NE、PAD4、MPO、citH3均显著高于脑膜瘤对照。
  • 血清中仅NE在GBM组显著升高,组织与血清标志物水平存在明显差异。
  • 组织PAD4诊断GBM的AUC为0.9568,判别效能最高,为最强独立预测因子。

核心结论

  • GBM肿瘤微环境中NETosis相关活性显著增强。
  • 肿瘤组织NETosis相关标志物尤其是PAD4可能为GBM诊断提供有意义的生物学信息。
  • NETosis通路可能构成理解GBM微环境生物学整体方法的一部分。

研究设计与样本

  • 前瞻性观察性研究,纳入42例组织病理学确诊并接受手术的GBM患者。
  • 对照组为38例颅内脑膜瘤患者(WHO I–III级)。
  • 采用ELISA检测术中肿瘤组织及配对术前血清中PAD4、MPO、NE和citH3水平。
  • 前瞻性记录血常规参数、炎症指数(NLR、PLR、SII)、肿瘤定位、术前肿瘤体积及Ki-67增殖指数。
  • 采用ROC曲线分析评估诊断效能,logistic回归分析识别独立预测因子。

主要发现

  • 肿瘤组织中NE、PAD4、MPO和citH3水平在GBM组均显著高于对照组(均p<0.0001)。
  • 血清样本中仅NE水平在GBM组显著升高(p<0.05)。
  • GBM队列中肿瘤组织PAD4、MPO和citH3水平显著高于血清(p<0.0001)。
  • 组织NE水平与肿瘤体积呈中度负相关(r=-0.412,p=0.007)。
  • ROC分析显示组织生物标志物诊断准确性高,PAD4判别效能最高(AUC=0.9568)。

关键数值与推荐

  • 肿瘤组织NE、PAD4、MPO、citH3在GBM组与对照组间差异均p<0.0001。
  • 血清NE在GBM组与对照组间差异p<0.05。
  • GBM组肿瘤组织PAD4、MPO、citH3均显著高于血清(p<0.0001)。
  • 组织NE与肿瘤体积相关系数r=-0.412,p=0.007。
  • 组织PAD4诊断GBM的AUC=0.9568。

临床怎么用

  • 术中获取的GBM肿瘤组织可检测NETosis相关标志物,其中PAD4诊断判别效能最高。
  • 血清NETosis标志物中仅NE在GBM中显著升高,单独用于诊断的价值有限。
  • 组织NETosis标志物可与炎症指数、Ki-67等多参数联合评估,辅助理解GBM微环境生物学。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma (GBM) is a primary brain tumor with a poor prognosis, characterized by profound immunosuppression and resistance to therapy. In recent years, neutrophil extracellular trap formation (NETosis) has been identified as a pro-tumoral mechanism in various malignancies; however, data on the concurrent and prospective evaluation of tissue and serum levels of NETosis-related biomarkers in GBM remain limited. METHODS: This prospective observational study included 42 patients with histopathologically confirmed GBM who underwent surgery and 38 patients with intracranial meningioma (WHO grades I–III) as controls. NETosis-related biomarkers, including peptidyl arginine deiminase 4 (PAD4), myeloperoxidase (MPO), neutrophil elastase (NE), and citrullinated histone H3 (citH3), were measured using ELISA in tumor tissue samples obtained intraoperatively and in paired preoperative serum samples. Hemogram parameters, inflammatory indices (NLR, PLR, and SII), tumor localization, preoperative tumor volume, and the Ki-67 proliferation index were prospectively recorded. Diagnostic performance was assessed using receiver operating characteristic (ROC) curve analysis, and independent predictors were identified by logistic regression analysis. RESULTS: In tumor tissue, levels of NE, PAD4, MPO, and citH3 were significantly higher in patients with GBM compared to the control group (all p < 0.0001). In serum samples, only NE levels were significantly elevated in the GBM group (p < 0.05). Within the GBM cohort, PAD4, MPO, and citH3 levels were significantly higher in tumor tissue than in serum (p < 0.0001). A moderate negative correlation was observed between tissue NE levels and tumor volume (r = − 0.412, p = 0.007). ROC analysis demonstrated high diagnostic accuracy for tissue biomarkers, with PAD4 showing the highest discriminative performance (AUC = 0.9568). In logistic regression analysis, all tissue biomarkers were significant predictors of GBM, with PAD4 emerging as the strongest determinant. CONCLUSIONS: This prospective study suggests that NETosis-related activity is pronounced within the GBM tumor microenvironment and demonstrates that NETosis-related biomarkers, particularly PAD4 measured in tumor tissue, may provide meaningful biological insights when evaluated together with multiple parameters. These findings support that NETosis pathways may constitute part of a holistic approach contributing to the understanding of glioblastoma microenvironment biology.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. İlikhan A, Taşdemir S, Oral Ş, et al. Evaluation of NETosis-related biomarkers in glioblastoma multiforme: PAD4 as a potent diagnostic predictor. J Neurooncol. 2026. PMID: 41703362. doi:10.1007/s11060-026-05469-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。